Jubilant Pharmova's Q2 Earnings Take A Bitter Pill, Net Profit Crashes 74% To ₹31 Crore Despite Generics Growth
Mumbai: Jubilant Pharmova Limited reported a sharp decline in profitability during the second quarter of FY27, with its net profit falling approximately 74% year-on-year to ₹31 crore, despite strong revenue growth in its generics and sterile injectables businesses. The pharmaceutical company reported total income of ₹2,384 crore for the quarter ended September 30, 2026. Jubilant Ingrevia Records…
Mumbai, September 30, 2026 - Jubilant Pharmova Limited, a leading pharmaceutical company, disclosed a significant drop in net profit during the second quarter of fiscal year 2027, despite a surge in revenue from its generics and sterile injectables businesses. Total income for the quarter amounted to ₹2,384 crore, with the company's net profit shrinking by approximately 74% to ₹31 crore, a dramatic decline from ₹120 crore during the same quarter last year.
Earnings before interest, tax, depreciation, and amortisation (EBITDA) also fell 27% year-on-year to ₹255 crore, indicating challenges in maintaining operating profitability. The generics segment exhibited robust growth, rising by 64% to ₹274 crore, while the CDMO sterile injectables business grew 33% to ₹522 crore. However, the Radiopharma business showed weaker performance, recording ₹1,009 crore in revenue.
In a strategic move, Jubilant Pharmova successfully raised ₹800 crore through non-convertible debentures (NCDs) to be used for debt refinancing and capital expenditure requirements.
Written by urgent.news from Free Press Journal's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
